Risk Evaluation and Mitigation Strategy (REMS): 18-Month Assessment Report of Dalfampridine Extended Release 10 mg Tablets

Time

Tue, Jun 26 11:00AM
T 01

Title

Risk Evaluation and Mitigation Strategy (REMS): 18-Month Assessment Report of Dalfampridine Extended Release 10 mg Tablets

Abstract Summary

Data from patient and prescriber surveys, a drug utilization study using Medco pharmacy and medical claims, an enhanced pharmacovigilance program, and Medication Guide distribution rates were used to assess effectiveness of the REMS program and to assess the need for changes to improve the program.

Poster Presenter

Calvin Mai
Astrazeneca Pharmaceuticals LP
United States

© 2015 DIA